Drug Target Review

APRIL 12, 2024

Starting from a single cell rather than bulk cells eliminates the need for post-transfection cell sorting, saving hands-on time and ensuring 100 percent monoclonality. This holds particular significance, as it is a prerequisite for FDA approval in biotechnology that any cell clones must originate from a single-cell progenitor.

Cell Biology 106

Cell Biology FDA Approval FDA Research 106

Drug Target Review

APRIL 12, 2024

Starting from a single cell rather than bulk cells eliminates the need for post-transfection cell sorting, saving hands-on time and ensuring 100 percent monoclonality. This holds particular significance, as it is a prerequisite for FDA approval in biotechnology that any cell clones must originate from a single-cell progenitor.

Cell Biology 98

Cell Biology FDA Approval FDA Research 98

Drug Target Review

SEPTEMBER 19, 2023

In spite of current success and possibility to be a successful cell technology model, the integration of organ-on-chips into drug development process needs more optimisation to be validated for FDA approval. From 3D cell culture to organs-on-chips. Trends in Cell Biology. 2010;328(5986):1662-8. Ingber DE.

Animal Testing 98

Animal Testing Clinical Trials Pharmaceutical Companies FDA 98

Drug Target Review

JUNE 5, 2023

His career efforts have led to the discovery and development of a range of FDA-approved and clinical-stage biologics for patients with difficult-to-treat cancers and autoimmune conditions. He brings over 25 years of US-based experience in biologics drug discovery and development in biotechnology research.

Treatment 101

Treatment Pharmacokinetics Drugs Cell Biology 101

Broad Institute

OCTOBER 11, 2023

By Allessandra DiCorato October 11, 2023 In 2011, Robert Manguso was working in a cell biology lab when his mother was diagnosed with Merkel cell carcinoma, a rare and aggressive skin cancer. They are used to treat cancers including melanoma and non-small cell lung cancer, but work only for a small fraction of patients.

Research 137

Research Immune Response Clinical Trials Therapies 137

Codon

APRIL 2, 2023

An open-source FACS automation system for high-throughput cell biology. Read Eisai and Biogen — companies behind the controversial, FDA-approved drug for Alzheimer’s, called Aduhelm — have published three additional papers with “detailed analyses” from their phase 2 trials. Might be useful!

DNA 52

DNA RNA Engineering Licensing 52

The Pharma Data

NOVEMBER 17, 2021

Realizing that their research could be relevant to inflammation associated with COVID-19, the duo reached out to Chris Sander, professor in residence of cell biology at HMS. The drug is FDA-approved and has been prescribed for over 60 years as a treatment for alcoholism. ” Sander recalled.

Virus 52

Virus Drugs Clinical Trials Medical Schools 52